TNFRSF17 and neoplasm: To achieve T-cell redirection alongside a tumor-restricted immune checkpoint blockade, a trispecific antibody (CDR101) that simultaneously targets BCMA, CD3, and PD-L1 has shown promise in the xenograft model [74].